Showing posts with label Pharmaceuticals. Show all posts
Showing posts with label Pharmaceuticals. Show all posts

Monday, April 14, 2008

Pay Off or Pay Out: What Pharma Corps Will Do to Sell You Drugs

Despite the dominant presence of pharmaceutical companies in psychiatry and their influence over clinical trials and research, the direction and focus of some current blogs I have explored reveal that there are others beside myself who are concerned with the current trend of drug treatment in the United States and the role these corporations are playing in it. The first post: “Drug Research: To Test or to Tout?” specifically addresses the issue of corporations such as Eli Lilly paying off state officials to get atypical antipsychotics put at the front of the market, causing doctors to prescribe patients drugs that cost far more and prove no more effective than their predecessors. These drugs, unlike ones before them, are also known to cause diabetes and severe weight gain. It follows the successes of Allen Jones, one of the current legal heads of the anti-pharmaceutical movement in psychiatry. The second post: “Pharma Pursues Its Wet Dream Legal Fantasy, Gets Paxil and Zoloft Suicide Lawsuits Denied” is a response to a current legal matter which has claimed Paxil and Zoloft victor of suicide lawsuits against their anti-depressant medications. Apparently, Zoloft and Paxil did not include increased risk of suicide on their lists of side effects despite several studies proving this to be true, and they are not being held accountable for risking the lives of consumers. However, the outcome of the case isn’t as important as the case itself. The fact that Zoloft and Paxil manufacturers attempted to hide such severe and fatal side effects from patients reveals the nature of the corporations producing them, and what they will do in order to increase sales. I have offered my own comments on both of these posts below, responding to the current issues with pharmaceutical companies and offering my own opinions and analysis.


Comment: "Drug Research: To Test or to Tout?"

First I would like to thank you for drawing the public eye to the questionable ethics of pharmaceutical corporations such as Eli Lilly. After having done extensive research on the effectiveness of atypical antipsychotics and their predecessors, it comes as no surprise to me that these new drugs are no more effective and pharmaceutical companies are doing everything they can to cash in on them anyway. Although this article does not address the greater issue of the severe negative effects of antipsychotics in general, giving consumers a reason to question their prescriptions and begin researching these drugs themselves is the ultimate goal, and this is definitely the type of provocative post that could cause such a phenomenon. It is important that patients realize that they can not rely solely on FDA approval as evidence that medications are safe and effective; that much of what the FDA approves is influenced by biased research conducted by these corporations, and that even those that the FDA attempts to restrain manage to spearhead through direct marketing to practicing physicians. In criticism, however, I would like to mention that many sources and studies are alluded to, but no direct references or links to references are given besides the link to the St. Petersburg Times. When confronting an issue of such a purely scientific nature with so much contention in the research field, linking to authoritative electronic resources is truly a necessity in order to drive home the point. Although a minor issue, I also believe this post could have been improved upon by use of graphics or visual media, as these elements are essential in harnessing a would-be reader’s attention. I only offer these suggestions because I truly believe in what your blog is doing. I am an avid reader of Atypical Antipsychotics and look forward to many more insightful posts in the future.


Comment: "Pharma Pursues its Wet Dream Legal Phantasy, Gets Paxil and Zoloft Suicide Lawsuits Denied"

Philip:
I’d like to start by thanking you for attacking the growing issue of pharmaceutical companies in an argumentative fashion that demands attention. I too believe that the growing power of the already colossal Big Pharma within the legal and research spheres is a frightening problem. However, I would like to contest your comment that “We all know that pharma companies dream about little but money and will go to damn near any length to create a market, hide problems with their drugs from the public and regulators, and manipulate their way to the latest blockbuster.” It is my belief that an epidemic of patient ignorance is the only thing truly responsible for these drugs becoming “the latest blockbuster.” If people understood that their marketing, their labels, and the doctors who prescribe them are not to be trusted, I would hope that sales would be on the decrease instead of the rise. Just from my personal experience with individuals on anti-depressants and anti-psychotic medications, I can say that there are still too many people who trust their drugs more than they trust themselves to cope with a problem. I agree with your response to the third circuit court’s ruling and I have little doubt that the reason for this ruling is checks being written on both sides of the table – in fact I just commented on another blog that addressed this issue in particular. The bigger pharmaceutical corporations get, the less chance anyone has of tackling them through the court system. This is why I believe our primary goal should be raising the awareness of consumers about the ineffective and destructive nature of antipsychotic and anti-depressant drugs. Your indirect approach to this matter is quite effective. If people start asking why Big Pharma would hide the suicide risk on drug labels, maybe they’ll start asking why doctors are prescribing them, and why they don’t seem to be getting any better. I appreciate your post and hope to see more like it in the future.

Monday, April 7, 2008

No Easy Way Out: The Depressing Reality of Anti-Depressants

The drawing to the rightis something I created in response to a disorder that I have experienced first hand: clinical depression. It is a work I created in expression of my fundamental belief that the power to overcome hardship and emotional trauma lies within nothing so much as the self. Depression is one of the most commonly treated psychiatric disorders in the United States, with anti-depressants being among the leading medications in sales within the pharmaceutical market. However, despite their popularity, the effectiveness of these drugs in the treatment of depression is not as miraculous as consumers would be led to believe. This is because no matter how well anti-depressants treat depression’s symptoms, they cannot treat the cause.

It is widely held that depression is caused by a chemical imbalance of the brain; that, because depression is caused by a chemical imbalance, it is something that a victim suffering from this illness has no control over. However, in spite of this common belief, there is little evidence to support it outside of research funded by the pharmaceutical companies which produce these drugs themselves. According to neuroscientist Elliot Valenstein “no biochemical or anatomical traits have been found to reliably distinguish the brains of the depressed, and attempts to prove the chemical deficiency hypothesis of depression have been in vain.” This would suggest that clinical depression is a very natural condition caused primarily by life experiences.

Whether or not antidepressants treat the cause, however, they will remain titans within the pharmaceutical market for the treatment of depression’s symptoms due to their heavily marketed effectiveness; for, as my previous posts have shown, the majority of psychiatrists and patients in the United States are already more concerned with alleviating the symptoms of mental illnesses rather than finding ways to cope with them. The majority of patients just want to feel better, whether their problems get solved or not. However, unlike anti-psychotics, an overwhelming amount of evidence suggests that antidepressants fail to treat even the symptoms of depression at a significantly higher rate than placebos. One of the largest studies ever done on anti-depressant drugs has concluded that they have “no clinically significant effect.” In this study, researchers conducted an analysis of the 47 published and unpublished clinical trials submitted to the Food and Drug Administration in the US made in support of the best known antidepressant drugs, including: Prozac, Seroxat and Efexor. The results proved the drugs ineffective in all but a very small portion of the most severely depressed.

It is of such importance for patients to be aware of what antidepressants do not do because of what they have been proven to be capable of. Long term doses of anti-depressants can actually lead to the patient becoming more depressed. This is because many of the side effects of antidepressants such as weight gain, sexual dysfunction and anxiety can cause a depressed state in people or make their depression more severe. Since depression is often if not always the result of life problems, adding more difficulties and stress on to those that drove the patient to take the medication in the first place can only cause the psychological state of the individual to worsen. Not only this, but according to Peter Breggin, M.D., the methods by which antidepressants reach–or attempt to reach–their desired effect inhibits the brain’s function and can lead to permanent, irreparable brain damage. There are also several published research studies which suggest that antidepressants increase a patient’s likelihood of attempting suicide–especially in the case of adolescents. These results can be especially problematic due to the deceiving nature of antidepressant withdrawal symptoms such as crying spells, irritability, anxiety and agitation. These symptoms can lead a patient to believe their depression has actually worsened and further medication is needed when such is not the case.

Although it is puzzling that antidepressant medications remain so widely trusted, believed in, and consumed in light of all the research that suggest their relative ineffectiveness, even more confounding is the use of off-label anti-psychotic drugs to treat depression. Currently twenty-one percent of anti-psychotics are prescribed for symptoms not indicated on the label and one of the few other disorders for which they are prescribed is depression. Considering several studies have shown, with little opposition, that anti-psychotics have absolutely no positive effect on depression, one need only read my prior posts on the negative effects of anti-psychotic pharmaceuticals to understand how grave an issue this is.

Why are antidepressants being prescribed when their effectiveness has such limited value and their side effects are so severe? Why are anti-psychotics being prescribed for something they do nothing about? For the same reasons that children younger than five are being prescribed them before they can say “I’m sad” and 67% of pharmaceutical companies negative research results remained unpublished (see chart). The majority of researchers involved in data collection are being sponsored by - or hold shares in - the very corporations producing the drugs, the doctors are getting paid to prescribe them, and the patients demand expensive placebos that make them feel better about the situations they don’t want to cope with.

Saturday, March 29, 2008

10 Ways to Stay Informed: Sites Dedicated to Mental Health

Continuing with my previous post “Mental Links: A Guide to the Authorities in Mental Health”, I have once again scoured the web for reliable and up-to-date resources to post for the assistance of others who wish for information on the topic of mental health. However, unlike my last post, these most recent links are more dedicated to information on pharmaceuticals and their misuse in the psychiatric field. As before, I have kept in mind the Webby Awards Criteria and the IMSA Criteria during my search and have offered here the top ten I have found to be most useful and authoritative.

DB’s Medical Rants, for one, is a blog covering a wide range of topics on health and pharmaceuticals. The blog, being posted by a very prestigious doctor, contains a great deal of authority and receives fresh posts on a daily basis, currently containing over 3000 posts. Unfortunately, “DB” does not make use of visual aids or graphics of any kind. “Atypical Antipsychotics”, another blog, shares this deficit. However, it makes up for this by being updated several times daily and providing recent information on harmful drugs in mental health and the negative effects of irresponsible prescriptions. Unlike these blogs, “The Last Psychiatrist” contains a humorous and entertaining twist to an otherwise grave topic, and manages to do so in a way that remains informative and insightful. Although the authority behind the author of “The Last Psychiatrist” is questionable, his sources are reliable. Stepping out of the blogosphere, I’d like to direct interested parties to “Psychiatric Services” and “Advances in Psychiatric Treatment”, two websites which feature online databases of medical journal PDFs in the psychiatric field; two sites most commendable on their levels of concrete and referenceable data and most lacking in their ease of direct navigation. If filtering through a massive selection of PDFs is too cumbersome, ScienceDaily or Pharmacy Choice might be better websites to visit. Both feature extensive and up-to-date news coverage on the latest in medical and pharmaceutical news but unfortunately lack the use of large, visually appealing graphics and multimedia. The Citizens Commission on Human Rights, being an organization dedicated to the investigation and exposure of human rights violations, is something all-together different. CCHR uses concrete evidence to reveal treatments harmful to patients, and offers healthy and beneficial alternatives. Following a similar field of interest is PsychRights, a law firm targeting these violations in the field of mental health. The site, although drab in its choice of colors and lacking visual quality, contains some very useful information relevant to the mistreatment of the mentally ill in psychiatry today. PsychSearch, a site which indexes case reports of such malpractice, is a very professional, model example of a page which makes proper use of colors and graphics while remaining easily navigable and with fast load times. As previously, all of these websites can be found in my linkroll posted on the right.

Monday, March 10, 2008

“Macha”: An Anti-Psychotic Community

"Macha"

Macha had always been unapproachable
Not just by her classmates and peers
but her teachers, her parents
felt powerless to relate with her

she wasn't unfriendly

nor her demeanor unpleasant
She was, simply put, an enigma
impossible to define
impossible to predict
Her style was not normal
nor was it rebellious
Her choice of music was unnerving
Celtic lullabies to death metal
There was no label
nothing relatable
The school counselor was suspicious
any child who didn't get along
didn't communicate
anyone undefinable
unpredictable
wasn't necessarily dangerous
but definately had something wrong
Were the parents abusive?
No cigarette burns to tell
No bruises, no cuts

Nothing at all

She seemed happiest alone, though
and there was crime in that
there were rumors too
of other things
unusual things
that she spoke to empty chairs
giggled at the oddest times
"spaced out" a bit too much in class
smiled at phantoms
and spent three days
walking a dead cat.
How much of this was true
was certainly questionable
She denied everything
As did her best friend
whose pleading was hopeless
considering her lack of substance
When they were alone,
Macha would explain that others
couldn't perceive her
because she wasn't real
but her friend simply couldn't understand
She knew that Macha wasn't crazy.
And only crazy people saw things others didn't
After several tests, Macha was defined.
Predicted.
Labeled.
Schizophrenic.
A single word that meant nothing
yet explained it all
A few weeks in the hospital
and a regular dose of antipsychotics
coupled with antidepressants
to relieve unpleasant side effects

And she should be Perfectly

normal

in no time.


"Macha, Patient 47A"

The binding on her wrists were tight, because they knew she would fight it.
She had dislocated her thumb three times in the past week trying to escape
She went for the gag first every time. It was remarkable.
The binds were as padded as could be without being escapable,
yet somehow, she had managed to make her wrists bleed again
she would make anything she could bleed when she got the chance
they had had to clip her nails uncomfortably short
so she wouldn't attempt to scratch her captors to death
or failing at that, gouge her way into her own throat
Fortunately the medications kept her mouth dry
or they would have had to swab out her spit
to keep her from choking on it.

They had to keep something in her mouth at all times
lest she bite off her own tongue

She was a difficult one to manage
with eyes that glowered with ire and defiance.
It had started with refusal to take meds.
Then institutionalization,
Now this.
Most of the staff refused to be anywhere within her general vicinity.
one member had even offered a letter of resignation.
When it was apparent that her behavior would not cease
They locked in a medicated stupor
tranquilized at the slightest upset

A drugged, unwilling surrender.



Epilogue: Are Antipsychotics Anti-Psychotic?

My purpose in creating the fictional “Macha,” as well as my artistic renditions of the work, is to address the typically unquestioned authority of antipsychotic medication as the first and last solution to mental disorders such as schizophrenia. The use of such drugs as exclusive treatment is a current and growing trend in the United States, and it is my belief that this is primarily due to intolerance or misinformation. Although it may be true that medication is widely accepted in psychiatry as an adequate suppressant of symptoms and is often necessary for the treatment of the most severe and dangerous forms of illness, there is an insurmountable amount of evidence to suggest that it does so at the cost of cognitive improvement, recovery, little permanent benefit, and with devastating long-term side-effects. Therefore, it should only be considered as a temporary solution, and even then, only in the most ominous of circumstances.

I created Macha to be an example of what happens when medication is considered before alternative, less detrimental and more productive methods of treatment have been exhausted. As in Macha's case, there is a high probability that the popularity of medication is due to its instant gratification, a deficiency in information, lack of required effort, and the dearth of tolerance and patience for mental illness. Antipsychotic treatments, as they function currently, aren’t designed for patients so much as for the short-term suppression of the unnerving characteristics of psychosis. The alternative–facing the unsettling nature of this disease, understanding it, and supporting those who experience it– should be the goal of not only patients’ guardians, but their communities, and society as a whole.

There is such an overwhelming amount of evidence and research to suggest that medication is not only an unproductive treatment but a hindrance to recovery, that it is astounding how widely accepted, promoted, prescribed and suggested antipsychotic medication is today. It is so unbelievable, that even as an informed individual backed by a small army of researchers with conclusive evidence to support my current conclusions, I am forced to second guess myself out of sheer lack of acknowledgement. How can so much evidence be ignored by practitioners? Are educators ignoring pertinent data? Are the doctors? Is the prescription of pharmaceuticals more profitable and thus ultimately better received? Whatever the reason, the current status quo among professionals is disregarding this research, and conclusively condemning the majority of uninformed patients to detrimental, unproductive and oft times unnecessary forms of treatment. Since the majority of patients trust and rely on their doctors for information, the current state of affairs is grim indeed.

A common misconception is that medication is required for the recovery of individuals with mental disorders such as schizophrenia. However, schizophrenia reverses naturally in the majority of its victims, and the highest rate of recovery has been observed in non-industrial countries where antipsychotics are not used. A fifteen-year multifollow-up study published by The Journal of Nervous and Mental Disease supports this claim, documenting the extreme disparity in recovery between schizophrenic patients who took antipsychotic medication and those who remained without it. According to their study, at the end of the fifteen-year period, twelve out of sixty-four patients were in a period of recovery. Of the sixty-four, twenty were not on any form of medication and eight of those twenty (fourty percent) were in a state of recovery; two of the thirty-nine patients on antipsychotics (five-percent) were recovering; and two out of five patients on medications but not antipsychotics were recovering. This article is not alone in its conclusion. One need only begin to browse the vast number of references it cites for further evidence. For even more authoritative research backing this conclusion, browse this index of authoritative articles dedicated to the subject.

M.D. Matt Irwin offers an explanation for why this lack of recovery in patients might occur. According to his extensive research, the physiology of people who have been exposed to antipsychotics and other drugs naturally adapt through “alterations in receptor number and function.” This "creates a physiological dependency which reinforces psychological dependency." The current emphasis of psychiatrists on drug treatment might also cause issues of social, psychological and spiritual nature to go unaddressed. A combination of these factors could worsen the outcomes, especially since tolerance of severe adverse effects of antipsychotics among patients is low and many choose not to take them unless forced to do so.

Obviously, the difference in recovery between patients on and off antipsychotic medications is not marginal. Even so, it can not be denied that there are plenty of cases of schizophrenia that are too severe to simply “cope with” and “tough out”. In such situations, antipsychotics might be necessary for short to mid-term therapy but should never be used as a primary or sole form of treatment. This is why anyone with a mental disorder or the guardian of anyone with a mental disorder–be it schizophrenia or otherwise–absolutely must educate themselves on evidence-based, alternative methods of treatment–treatment which offers permanent recovery benefits whether or not the individual requires a term of medication. A method that has been proven effective in multiple cases is cognitive behavior therapy (CBT). This system uses mental techniques such as developing alternative explanations for symptoms, and altering thought processes to “reduce the severity of, or distress from, the symptom regardless of whether the patient accepts a diagnostic label.” One of the greatest advantages of cognitive behavior therapy is that it does not rely on the patient accepting his or her symptoms as a function of a mental illness in order to be effective. In fact, in the United States, American-based guidelines for treatment of schizophrenia such as those issued by the American Psychiatric Association and the schizophrenia patient outcomes research team recommend cognitive behavior therapy for treatment-resistant patients for this very reason. However, it is unfortunate that in the United States only the stubbornly defiant are receiving what the United Kingdom has already accepted as adequate, acceptable and readily available treatment. An article printed in the American Journal of Psychiatry titled “Cognitive Behavior Therapy for Schizophrenia” specifically addresses the lack of cognitive behavior therapy as a primary method of treatment in the United States in comparison to the UK and the severity of this issue due to its empirically researched and supported benefits.

One example of such an examination is an piece studying cognitive behavioral therapy in schizophrenics with command auditory hallucinations, which found that patients undergoing this form of therapy had fewer episodes, complied to auditory hallucinations less, and generally acted in less ways to appease them. Although the hallucinations did not cease, they became less of a hindrance and burden on the lives of patients. Conductors of another, similar study discovered that after one year, patients who had undergone cognitive behavioral therapy, starting at the time of hospitalization and while acutely psychotic, benefited greatly over those who did not receive this therapy. They noted that the benefits extended to both the positive and negative symptoms of schizophrenia as well as overall social interaction.

Even though the severity of schizophrenic symptoms may require temporary treatment with antipsychotics, this represents a minority of cases. Those who wish to undergo such treatment, and guardians who are considering putting their children on antipsychotics should be fully aware of the long-term consequences, increased relapse rates, drug withdrawal symptoms, decreased probability of recovery and side-effects. They should also be relieved of any disillusions that these pharmaceuticals are a completely safe and effective form of treatment, because there is plenty of evidence to suggest otherwise. The greatest offense a guardian, or the community responsible for an individual’s care can commit, is medicating a person with a mental disorder out of sheer convenience. Antipsychotics are quick, easy and deceptively effective at suppressing symptoms, but their aid ends there. In and of themselves they are not, and should not be considered a healthy, productive form of treatment.

 
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 Unported License.